NEWSROOM
Press Releases by Agendia
News
Press Releases
New Data Shows Agendia’s MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS) included 840 women at 58 US institutions. 45% of patients with an intermediate/indeterminate Recurrence Score from a 21-gene assay OncotypeDx Read More
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board
Company also announces new ASCO data presentation from the prospective PROMIS study assessing the clinical impact of the definitive MammaPrint 70-gene assay results for patients previously classified as indeterminate by the 21-gene assay (OncotypeDx) IRVINE, Read More
MINDACT in the News
News, videos, social media and more about the recently released MINDACT phase III, prospective randomized trial results The primary analysis from the MINDACT clinical trial was presented by Martine Piccart, MD, PhD at the American Association for Read More
Agendia Appoints Dr. M. William Audeh to Chief Medical Officer
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, recently announced the appointment of veteran medical oncologist M. William Audeh, MD, MS to the position of Chief Read More
Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 percent node-positive, had five-year distant metastasis-free survival rate in excess of 94 percent, whether randomized to receive adjuvant chemotherapy or not MammaPrint could change clinical Read More
MINDACT results will be presented during the AACR Annual Meeting 2016
EORTC (European Organisation for Research and Treatment of Cancer), BIG (Breast International Group), and Agendia are pleased to announce that the “Primary analysis of the EORTC 10041/ Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays and their clinical relevance at the 2016 Miami Breast Cancer Conference (MBCC) IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader in personalized medicine Read More
